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Purpose of the study
To evaluate efficacy, tolerability and safety of raltegravir
(expanded access program) in HIV multi-experience
patients.
Methods
Observational study to analyse immune and virological
response, and incidence of adverse events during raltegra-
vir therapy. Transaminase elevation(TE) was scored
according to increase in ALT value 2.6–5× upper normal
limit (toxicity grade 2), 5.1–10× upper normal limit (tox-
icity grade 3) and >10× upper normal limit (toxicity grade
4). To avoid bias related to patients with high baseline
serum ALT and AST levels, TE was defined by increase in
ALT value 2.6–3.5× (toxicity grade 2), 3.6–5× (toxicity
grade 3), and >5× (toxicity grade 4) the baseline value.
Metabolic and renal profile were assessed at baseline, after
1 month and every 3 months. 103 HIV+ patients have
been enrolled; 37 patients were HCV or HBV co-infected.
CDC group was 50C, 34B and 19A. Previous therapeutic
mean lines was 9.1; mean mutations were 5.5 for NRTI
and 8.6 for PI.
Summary of results
Mean follow-up is 177 ± 80 days (range 55–450). Five
patients stopped all HIV therapy for personal decisions
without side-effect. Most frequent associated protease
inhibitor was darunavir (77 patients) and 10 patients had
TMC125 and seven had T20 associated with raltegravir.
Mean CD4 and HIV-RNA values at baseline were 279
cells/mm3 and 3.89 log cp/ml, respectively; during the
follow-up there was an increase of CD4 count (344 cells/
mm3) and a decrease in viral load (1.69 log) which was
statistically significant (p < 0.0001). One patient had no
viral suppression and four patients had a viral failure
(HIV-RNA<1,000 cp/ml) after 6 months of therapy. Only
two HCV-positive patients had an increase in transami-
nase value grade 2. One patient developed NH lym-
phoma, One patient had an acute myocardial infarction
and one patient in dialysis underwent to renal transplan-
tation; none of the patients stopped raltegravir. No statis-
tically significant modification has been seen in ALT, AST,
GGT, creatinine, glucose, triglycerides values. Only total
cholesterol showed a statistically significant increase (p =
0.0115 and p = 0.0442) at 3 (196 mg/dl) and 6 (189 mg/
dl) months, probably due to boosted protease inhibitor
association; 48 patients had at baseline cholesterol values
in the upper normal limit and the lipid profile did not
worsen during follow-up.
Conclusion
Raltegravir was well tolerated and efficient in all patients
and showed a good metabolic, renal and liver profile in
our cohort where the rate of co-infected patients was high.
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